KLDO — Kaleido Biosciences, Inc.
$0.00
+$0.00 (+0.00%)
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
Market Cap
$4262.00
Forward P/E
-0.0x
52-Week Range
N/A
KLDO Price History
Revenue vs. Net Income
$1.1M
Revenue · FY2021
Annual. Net margin is shown under each year.
Free Cash Flow
-$78.2M
FCF · FY2021
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-427.5%
ROCE · FY2021
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.3x
Assets ÷ liabilities · FY2021
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
102.3%
CapEx · FY2021
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
42.6M
Diluted shares · FY2021
Only one year of share data is available, so no change can be shown yet.
